Cobenfy — The First Novel Schizophrenia Mechanism in 70 Years

Cobenfy is the most consequential single-product story at BMS — the first new mechanism for treating schizophrenia in over 70 years, the centerpiece of the $14B Karuna acquisition, and the bet that anchors much of Boerner's pipeline narrative. Candidates in neuroscience, commercial, market access, R&D, and even general roles need to be able to discuss it intelligently, including the recent ADEPT-2 setback.